Cargando…

Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene

OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Sui, Zhi-lin, Wu, Xian-xian, Tang, Peng, Zhang, Hong-dian, Yu, Zhen-tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092352/
https://www.ncbi.nlm.nih.gov/pubmed/33953601
http://dx.doi.org/10.2147/PGPM.S302755
_version_ 1783687645385195520
author Wang, Hao
Sui, Zhi-lin
Wu, Xian-xian
Tang, Peng
Zhang, Hong-dian
Yu, Zhen-tao
author_facet Wang, Hao
Sui, Zhi-lin
Wu, Xian-xian
Tang, Peng
Zhang, Hong-dian
Yu, Zhen-tao
author_sort Wang, Hao
collection PubMed
description OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis. RESULTS: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance. CONCLUSION: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity.
format Online
Article
Text
id pubmed-8092352
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80923522021-05-04 Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene Wang, Hao Sui, Zhi-lin Wu, Xian-xian Tang, Peng Zhang, Hong-dian Yu, Zhen-tao Pharmgenomics Pers Med Original Research OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis. RESULTS: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance. CONCLUSION: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity. Dove 2021-04-28 /pmc/articles/PMC8092352/ /pubmed/33953601 http://dx.doi.org/10.2147/PGPM.S302755 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Hao
Sui, Zhi-lin
Wu, Xian-xian
Tang, Peng
Zhang, Hong-dian
Yu, Zhen-tao
Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title_full Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title_fullStr Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title_full_unstemmed Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title_short Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
title_sort reversal of chemotherapy resistance to cisplatin in nsclc by mirna-195-5p via targeting the fgf2 gene
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092352/
https://www.ncbi.nlm.nih.gov/pubmed/33953601
http://dx.doi.org/10.2147/PGPM.S302755
work_keys_str_mv AT wanghao reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene
AT suizhilin reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene
AT wuxianxian reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene
AT tangpeng reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene
AT zhanghongdian reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene
AT yuzhentao reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene